Estrogen receptor status and response to chemotherapy in advanced breast cancer: the Tufts-Shattuck-Pondville experience.
Eighty-eight patients with advanced breast cancer were retrospectively reviewed to compare estrogen receptor (ER) data with response to cytotoxic chemotherapy. All assays were done in a single laboratory. All patients were cared for at a single institution. Thirty-four patients were treated with chemotherapy, 30 of whom were evaluable for response by criteria of the Eastern Cooperative Oncology Group (ECOG). Of 16 ER-positive patients, 12 (75%) responded; of 14 ER-negative patients, six (43%) responded (P < 0.05). The two groups did not differ significantly in chemotherapy received, menopausal status, site of predominant disease, stage at diagnosis, or disease-free interval. Response to cytotoxic chemotherapy does not appear to correlate with ER status.
D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011241:Prednisone